Literature DB >> 19684080

Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage.

Magdia De Jesus1, André Moraes Nicola, Susana Frases, Ian R Lee, Steven Mieses, Arturo Casadevall.   

Abstract

The mechanisms responsible for polysaccharide-induced immunological paralysis have remained unexplained almost a century after this phenomenon was first described. Cryptococcus neoformans capsular polysaccharides glucuronoxylomannan and galactoxylomannan (GalXM) elicit little or no Ab responses. This study investigates the immunological and biological effects of GalXM in mice. GalXM immunization elicits a state of immunological paralysis in mice characterized by the disappearance of Ab-producing cells in the spleen. Immunological paralysis and lack of immunogenicity could not be overcome by immunization with GalXM conjugated to a protein carrier, Bacillus anthracis protective Ag. Additionally, immunization with GalXM in either complete or IFA was associated with spleen enlargement in BALB/c mice. TUNEL and flow cytometry revealed widespread apoptosis in the spleen after GalXM administration. Administration of a cocktail of caspase-3 inhibitor Z-DEVD-FMK and general caspase inhibitor Z-VAD-FMK or Fas-deficient mice abrogated the complete disappearance of Ab-producing cells. Analysis of spleen cytokine expression in response to GalXM systemic injection revealed that GalXM down-regulated the production of inflammatory cytokines. Hence, we conclude that GalXM-induced immune paralysis is a result of specific B cell depletion mediated by its proapoptotic properties in the context of widespread dysregulation of immune function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684080      PMCID: PMC2737596          DOI: 10.4049/jimmunol.0900449

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Active immunization against Cryptococcus neoformans.

Authors:  H H GADEBUSCH
Journal:  J Infect Dis       Date:  1958 May-Jun       Impact factor: 5.226

Review 2.  Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity.

Authors:  A Vecchiarelli; A Casadevall
Journal:  Res Immunol       Date:  1998 May-Jun

Review 3.  A primer on cytokines: sources, receptors, effects, and inducers.

Authors:  J H Curfs; J F Meis; J A Hoogkamp-Korstanje
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

4.  Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.

Authors:  N Lendvai; A Casadevall; Z Liang; D L Goldman; J Mukherjee; L Zuckier
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.

Authors:  A Vecchiarelli; C Retini; C Monari; A Casadevall
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

6.  Expression and biologic characterization of the murine chemokine KC.

Authors:  C R Bozic; L F Kolakowski; N P Gerard; C Garcia-Rodriguez; C von Uexkull-Guldenband; M J Conklyn; R Breslow; H J Showell; C Gerard
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

7.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Monoclonal antibody based ELISAs for cryptococcal polysaccharide.

Authors:  A Casadevall; J Mukherjee; M D Scharff
Journal:  J Immunol Methods       Date:  1992-09-18       Impact factor: 2.303

9.  Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67.

Authors:  V V Vaishnav; B E Bacon; M O'Neill; R Cherniak
Journal:  Carbohydr Res       Date:  1998-01       Impact factor: 2.104

10.  Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.

Authors:  J Mukherjee; A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

View more
  15 in total

1.  Heterocycle Thiazole Compounds Exhibit Antifungal Activity through Increase in the Production of Reactive Oxygen Species in the Cryptococcus neoformans-Cryptococcus gattii Species Complex.

Authors:  Nívea Pereira de Sá; Caroline Miranda de Lima; Cleudiomar Inácio Lino; Paulo Jorge Sanches Barbeira; Ludmila de Matos Baltazar; Daniel Assis Santos; Renata Barbosa de Oliveira; Eleftherios Mylonakis; Beth Burgwyn Fuchs; Susana Johann
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

3.  The tetraspanin CD82 is specifically recruited to fungal and bacterial phagosomes prior to acidification.

Authors:  Katerina Artavanis-Tsakonas; Pia V Kasperkovitz; Eliseo Papa; Michael L Cardenas; Nida S Khan; Annemarthe G Van der Veen; Hidde L Ploegh; Jatin M Vyas
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

4.  Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage.

Authors:  Eva Pericolini; Elena Gabrielli; Giovanni Bistoni; Elio Cenci; Stefano Perito; Siu-Kei Chow; Francesca Riuzzi; Rosario Donato; Arturo Casadevall; Anna Vecchiarelli
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

5.  Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans.

Authors:  Christian Heiss; Michael L Skowyra; Hong Liu; J Stacey Klutts; Zhirui Wang; Matthew Williams; Deepa Srikanta; Stephen M Beverley; Parastoo Azadi; Tamara L Doering
Journal:  J Biol Chem       Date:  2013-02-13       Impact factor: 5.157

6.  Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable.

Authors:  Magdia De Jesus; Siu-Kei Chow; Radames J B Cordero; Susana Frases; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2010-01-08

Review 7.  Programmed Cell Death: Central Player in Fungal Infections.

Authors:  Giorgio Camilli; Mariana Blagojevic; Julian R Naglik; Jonathan P Richardson
Journal:  Trends Cell Biol       Date:  2020-12-05       Impact factor: 20.808

8.  Spontaneous inflammatory pain model from a mouse line with N-ethyl-N-nitrosourea mutagenesis.

Authors:  Tsung-Chieh Chen; José Jiun-Shian Wu; Wei-Pang Chang; Ping-Ning Hsu; Sung-Tsang Hsieh; Bai-Chuang Shyu
Journal:  J Biomed Sci       Date:  2012-05-30       Impact factor: 8.410

9.  Biology and function of exo-polysaccharides from human fungal pathogens.

Authors:  Krystal Y Chung; Jessica C S Brown
Journal:  Curr Clin Microbiol Rep       Date:  2020-01-17

10.  The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.

Authors:  Eva Pericolini; Alessia Alunno; Elena Gabrielli; Elena Bartoloni; Elio Cenci; Siu-Kei Chow; Giovanni Bistoni; Arturo Casadevall; Roberto Gerli; Anna Vecchiarelli
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.